Latest news
How (ELVN) Movements Inform Risk Allocation Models - Stock Traders DailyStock Traders Daily · Mon, 10 Aug 2026 04:04:02 GMTLifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70 - MoomooMoomoo · Sat, 08 Aug 2026 14:31:00 GMTLifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - MoomooMoomoo · Sat, 08 Aug 2026 03:55:41 GMTEnliven Therapeutics (ELVN) director exercises options, sells 158,795 shares - Stock TitanStock Titan · Fri, 07 Aug 2026 02:15:04 GMTInsider Sale: Director at $ELVN Sells 158,795 Shares - MoomooMoomoo · Fri, 07 Aug 2026 00:32:10 GMTA Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82 - MoomooMoomoo · Thu, 06 Aug 2026 22:49:06 GMTEnliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common shares - BitgetBitget · Thu, 06 Aug 2026 16:18:43 GMTFMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership - Stock TitanStock Titan · Thu, 06 Aug 2026 14:21:20 GMT